Detalhe da pesquisa
1.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
2.
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Ann Hematol
; 102(4): 863-876, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36862168
3.
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Blood
; 136(1): 71-80, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244252
4.
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Am J Hematol
; 97(6): 719-730, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35293006
5.
Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019.
Eur J Haematol
; 107(4): 428-435, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34137077
6.
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Blood
; 130(8): 974-981, 2017 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28637662
7.
A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.
Kidney Int
; 94(1): 199-205, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29759418
8.
Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders.
Br J Haematol
; 180(1): 71-81, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29105742
9.
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.
N Engl J Med
; 373(11): 1040-7, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26352815
10.
Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis.
Blood
; 127(19): 2275-80, 2016 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26907632
11.
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
Blood
; 128(1): 37-44, 2016 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27216216
12.
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Blood
; 128(3): 384-94, 2016 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27222480
13.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Lancet
; 387(10027): 1551-1560, 2016 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26778538
14.
Reappraisal of risk factors for monoclonal gammopathy of undetermined significance.
Am J Hematol
; 91(6): 581-4, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26953904
15.
Proteasome inhibitor associated thrombotic microangiopathy.
Am J Hematol
; 91(9): E348-52, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27286661
16.
How I treat monoclonal gammopathy of renal significance (MGRS).
Blood
; 122(22): 3583-90, 2013 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24108460
17.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Lancet Oncol
; 15(12): e538-48, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25439696
18.
19.
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis.
Blood
; 118(7): 1979-88, 2011 Aug 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-21690560
20.
Racial disparities in incidence and outcome in multiple myeloma: a population-based study.
Blood
; 116(25): 5501-6, 2010 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-20823456